Treatment of patients with Olmsted syndrome (gain-of function mutation Gly573Cys) by the EGFR inhibitor erlotinib led to positive results a rapid significant improvement in the symptoms of palmoplantar keratoderma (PPK), including pain and itch. Here, EGFR is linked to Olmsted syndrome.